Flolan ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	14

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

diseases per page:

Showing 1 to 10 of 14 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02705807 (ClinicalTrials.gov)	May 2016	25/2/2016	Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects	An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLAN™ in Japanese Sub ...	Cardiovascular Disease	Drug: FLOLANinjection with currently marketed diluent;Drug: FLOLANinjection with reformulated diluen ...	GlaxoSmithKline	NULL	Completed	18 Years	75 Years	All	10	Phase 4	Japan
2	EUCTR2011-002943-92-NL (EUCTR)	07/11/2011	22/08/2011	Study of a new thermostable formulation of Flolan™ to treat Pulmonary Arterial Hypertension (PAH)	A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation ...	pulmonary arterial hypertension (PAH) MedDRA version: 14.1;Level: PT;Classification code 10064911;Te ...	Trade Name: FLOLAN™ and Glycine Diluent Product Name: FLOLAN™ and Glycine Diluent Product Code: 4AU76 I ...	GlaxoSmithKline Research and Development Limited	NULL	Not Recruiting			Female: yes Male: yes	20		United States;Canada;Netherlands
3	NCT01462565 (ClinicalTrials.gov)	November 1, 2011	13/10/2011	Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hyperten ...	A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation ...	Hypertension, Pulmonary	Drug: current marketed FLOLAN(epoprostenol sodium);Drug: new thermo stable formulation of epoprosten ...	GlaxoSmithKline	NULL	Completed	18 Years	75 Years	All	16	Phase 4	United States;Canada;Netherlands
4	EUCTR2010-018322-40-NL (EUCTR)	11/07/2011	19/07/2011	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	Pulmonary Arterial Hypertension MedDRA version: 12.1;Level: LLT;Classification code 10064911;Term: P ...	Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-3857 ...	ACTELION Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	35	Phase 3	Netherlands;Belgium;France;Spain;Italy
5	EUCTR2010-018322-40-ES (EUCTR)	17/06/2011	03/11/2011	Estudio de investigación clínica para evaluar la seguridad de cambiar el Flolanpor un nuevo fármaco ...	Estudio de fase 3b multicéntrico, de una única rama, abierto para evaluar los efectos de cambiar de ...	Hipertensión Arterial Pulmonar (HAP) MedDRA version: 14.0;Level: PT;Classification code 10064911;Ter ...	Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-3857 ...	Actelion Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	35	Phase 3	France;Canada;Belgium;Spain;Netherlands;Italy
6	EUCTR2010-018322-40-IT (EUCTR)	04/05/2011	05/01/2012	A clinical research study to evaluate the safety of changing from Flolanto a new drug called Epopros ...	Uno studio multicentrico, a braccio singolo, in aperto, di fase 3b, per valutare gli effetti del pas ...	Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pu ...	Trade Name: Epoprostenolo per iniezione INN or Proposed INN: Epoprostenol Trade Name: Epoprostenol for ...	Actelion Pharmaceuticals Ltd.	NULL	Not Recruiting			Female: yes Male: yes	40		Canada;Netherlands;Belgium;France;Spain;Italy
7	NCT01431716 (ClinicalTrials.gov)	March 2011	7/9/2011	Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	Pulmonary Arterial Hypertension	Drug: EFI/ACT-385781A	Actelion	NULL	Completed	18 Years	N/A	All	42	Phase 3	Belgium;Canada;France;Italy;Netherlands;Spain
8	EUCTR2010-018322-40-BE (EUCTR)	02/07/2010	07/04/2010	A clinical research study to evaluate the safety of changing from Flolanto a new drug called Epopros ...	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pu ...	Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-3857 ...	ACTELION Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 3	France;Canada;Spain;Belgium;Netherlands;Italy
9	EUCTR2010-018322-40-FR (EUCTR)	20/05/2010	29/03/2010	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	Pulmonary Arterial Hypertension MedDRA version: 12.1;Level: LLT;Classification code 10064911;Term: P ...	Trade Name: Epoprostenol-Actelion Product Name: Epoprostenol-Actelion Product Code: ACT-385781A INN or ...	ACTELION Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 3	France;Spain;Belgium;Netherlands;Italy
10	NCT01105117 (ClinicalTrials.gov)	May 2010	15/4/2010	Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401	An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A ...	Pulmonary Arterial Hypertension	Drug: ACT-385781A (Actelion Epoprostenol);Drug: Flolan®	Actelion	NULL	Completed	18 Years	65 Years	All	2	Phase 4	United States

First Previous1 2Next Last